Rockwell Medical (NASDAQ:RMTI) Rating Increased to Strong-Buy at RODMAN&RENSHAW

RODMAN&RENSHAW upgraded shares of Rockwell Medical (NASDAQ:RMTI) to a strong-buy rating in a report published on Thursday,Zacks.com reports.

A number of other analysts have also weighed in on the stock. Rodman & Renshaw initiated coverage on shares of Rockwell Medical in a research report on Thursday. They issued a “buy” rating and a $5.00 price objective on the stock. StockNews.com upgraded Rockwell Medical from a “hold” rating to a “buy” rating in a report on Wednesday, November 13th. Finally, HC Wainwright restated a “buy” rating and set a $9.00 price objective on shares of Rockwell Medical in a report on Wednesday, September 11th.

Rockwell Medical Trading Down 5.2 %

RMTI stock opened at $2.36 on Thursday. Rockwell Medical has a twelve month low of $1.16 and a twelve month high of $5.15. The stock has a market capitalization of $76.28 million, a price-to-earnings ratio of -47.10 and a beta of 1.50. The company has a quick ratio of 1.60, a current ratio of 2.41 and a debt-to-equity ratio of 0.33. The firm’s fifty day simple moving average is $3.68 and its two-hundred day simple moving average is $2.62.

Institutional Investors Weigh In On Rockwell Medical

Several large investors have recently added to or reduced their stakes in the stock. Concurrent Investment Advisors LLC bought a new stake in shares of Rockwell Medical during the third quarter valued at approximately $40,000. Verus Capital Partners LLC purchased a new stake in shares of Rockwell Medical in the 3rd quarter worth $51,000. Barclays PLC bought a new position in shares of Rockwell Medical during the 3rd quarter worth $90,000. Beacon Financial Advisory LLC purchased a new position in shares of Rockwell Medical during the third quarter valued at $98,000. Finally, XTX Topco Ltd raised its holdings in shares of Rockwell Medical by 45.7% in the third quarter. XTX Topco Ltd now owns 28,455 shares of the company’s stock valued at $113,000 after acquiring an additional 8,922 shares in the last quarter. 23.31% of the stock is owned by hedge funds and other institutional investors.

Rockwell Medical Company Profile

Rockwell Medical, Inc, together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis.